Jakinibs for the Treatment of Immune Dysregulation in Patients With Gain–of–Function Signal Transducer and Activator of Transcription 1 (STAT1) or STAT3 Mutations

LR Forbes, TP Vogel, MA Cooper. J Allergy Clin Immunol. 2018;142(5):1665–1669 To investigate the efficacy of jakinib therapy in patients with gain-of-function (GOF) signal transducer and activator of transcription 1 (STAT1) or signal transducer and activator of transcription 3 (STAT3) mutations. The study included 17 total patients with either a STAT1 GOF ( n = 11) or STAT3 GOF ( n = 6) mutation who were treated with jakinibs (ruxolitinib or tofacitinib). Patients came from 11 international centers. This was a retrospective study to describe disease-related clinical manifestations and determine …